Abstract 415P
Background
Blood-based MCED testing has emerged as a promising paradigm for earlier detection of cancer, which is associated with better outcomes. Little is known about the real-world performance of such assays in Asia. A ctDNA mutation-based MCED assay (LucenceINSIGHT), reports cancer signal (CS) status in plasma, and additionally predicts tissue-of-origin for up to 10 cancers where identifiable. We report here real-world results of the initial cohort.
Methods
Targeted ultrasensitive amplicon-based next-generation sequencing (NGS) with mirror barcodes is used to detect CS status by detecting cancer-associated mutations and viral DNA in 84 genes in plasma cell-free DNA (cfDNA). Matched white blood cell DNA was analyzed to exclude clonal hematopoiesis as a contributor. Consecutive results from 264 subjects (1/2023 - 6/2023) from Singapore, Hong Kong and Malaysia that underwent testing at a CAP-accredited, CLIA-certified laboratory were included in the analysis.
Results
were returned for 100% of subjects with a mean turnaround time of 14.1 calendar days. Mean age was 55.1 years (yrs) with 61.4% being male. CS-positive rate was 1.1% (3/264). All 3 CS-positive subjects were male, >40 years of age and were asymptomatic and without known cancer at screening. All 3 subsequently had neoplasms confirmed (locally advanced colon cancer, localized kidney cancer, and myeloproliferative neoplasm), for a specificity and PPV of 100%. 2 of 3 of these cases (kidney and myeloproliferative neoplasm) would not have been covered under traditional screening guidelines. One subject with CS-negative test results had a suspected cholangiocarcinoma at the point of test order, for an overall sensitivity of 75%.
Conclusions
We report initial experience with a cohort undergoing amplicon-based MCED testing in Asia, with a real-world CSD rate of 1.1%, consistent with previous ctDNA-based cancer screening studies in the USA. A majority of cases detected were not covered under traditional screening guidelines. These findings provide additional support for the use of ultrasensitive mutation-based assays for screening.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Lucence Diagnostics Pte Ltd.
Funding
Lucence Diagnostic Pte Ltd.
Disclosure
M. Pek, C. Hao, Z.Y. Wan, J. Poh, M. Tan: Financial Interests, Institutional, Full or part-time Employment: Lucence Diagnostics. M. Tan: Financial Interests, Institutional, Full or part-time Employment: Lucence Diagnostics; Financial Interests, Institutional, Stocks or ownership: Lucence Diagnostics. All other authors have declared no conflicts of interest.
Resources from the same session
529P - Ramucirumab plus docetaxel after combination chemoimmunotherapy in patients with non-small cell lung cancer: A prospective observational study
Presenter: Tadaaki Yamada
Session: Poster Display
Resources:
Abstract
530P - MYC recruits tumor-associated macrophage to sustain metastatic malignancy of lung adenocarcinoma micropapillary subtype through epigenetic reprogramming
Presenter: Xuming Song
Session: Poster Display
Resources:
Abstract
531P - Effect of combinational targeted therapy for AXL and ATR against malignant mesothelioma cells
Presenter: Soichi Hirai
Session: Poster Display
Resources:
Abstract
532P - The changes of the serum SMRP levels is useful to predict the antitumor efficacy of ipilimumab plus nivolumab combination therapy in patients with malignant pleural mesothelioma
Presenter: Taiichiro Otsuki
Session: Poster Display
Resources:
Abstract
533P - Efficacy in the elderly NSCLC patients in SCORPION study: Phase II study of DTX plus RAM following platinum-based chemotherapy plus ICIs
Presenter: Teppei Yamaguchi
Session: Poster Display
Resources:
Abstract
534P - DSC2 promotes the proliferation, metastasis and drug resistance of lung cancer by activating the PI3K/AKT pathway
Presenter: Qi Li
Session: Poster Display
Resources:
Abstract
535P - Alteration in NKX2-1 CN reshapes the oncogenic, immunologic, and prognostic landscapes in NSCLC
Presenter: Herdee Gloriane Luna
Session: Poster Display
Resources:
Abstract
536P - The evaluation and long-term outcome of pulmonary metastasectomy for osteosarcoma: A 20-year experience of Shanghai Rujin Hospital
Presenter: Zhusheng Zhang
Session: Poster Display
Resources:
Abstract
537P - The impact of treatment-free interval on patient outcome after pulmonary metastasectomy for sarcoma
Presenter: Po-Kuei Hsu
Session: Poster Display
Resources:
Abstract
538P - First-line chemoimmunotherapy for metastatic thymic carcinoma
Presenter: Victoria Andreas
Session: Poster Display
Resources:
Abstract